Promoting drug discovery by collaborative innovation: A novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare

Drug Discovery Today

Volumn 17, Issue 21-22, 2012, Pages 1242-1248

  Wellenreuther, Ruth ^a   Keppler, Dietrich ^a   Mumberg, Dominik ^b   Ziegelbauer, Karl ^b   Lessl, Monika ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BIOLOGICAL THERAPY; BIOTECHNOLOGY; CANCER CENTER; CANCER RESEARCH; DRUG DESIGN; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HEALTH CARE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; INTERPERSONAL COMMUNICATION; KNOWLEDGE; MEDICAL DECISION MAKING; PERSONNEL MANAGEMENT; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP; REIMBURSEMENT; REINFORCEMENT; REVIEW; REWARD; RISK BENEFIT ANALYSIS; RISK FACTOR; TRUST;

BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; GERMANY; HUMANS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 84868123718     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.04.004     Document Type: Review

References (16)

1. M. Senior, and E.F. Licking Back to school: Big Pharmas test new models for tapping academia In Vivo: The Business and Medicine Report 2011 Elsevier Available at: http://www.elsevierpharma.com/articles/back-school-big-pharmas- test-new-models-tapping-academia
2. J. Kling Biotechs follow big pharma lead back into academia Nat. Biotechnol. 29 2011 555 556
3. M. Ratner Pfizer reaches out to academia - again Nat. Biotechnol. 29 2011 3 4
4. S. Mayhew Trends in discovery externalization Nat. Rev. Drug Discov. 9 2011 182 183
5. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
6. W. Peng Drug pipeline: Q311 Nat. Biotechnol. 29 2011 859
7. F.L. Douglas, and L. Mitchell Assessing Risk and Return: Personalized Medicine Development & New Innovation Paradigm 2008 Erwing Marion Kauffman Foundation Available at: http://www.kauffman.org/uploadedFiles/HHS-White-Paper- 1008.pdf
8. M. Lessl Crowd sourcing in drug discovery Nat. Rev. Drug Discov. 10 2011 241 242
9. A. Mullar An audience with Francis Collins Nat. Rev. Drug Discov. 10 2011 14
10. N. Moran New models emerge for commercializing university assets Nat. Biotechnol. 29 2011 774 775
11. M. Lessl, and F. Douglas From technology transfer to know-how interchange Wissenschaftsmanagement 2 2010 34 41
12. I. Gashaw What makes a good drug target? Drug Discov. Today 16 2011 1037 1043
13. A.M. Edward Open access chemical and clinical probes to support drug discovery Nat. Chem. Biol. 5 2009 436 440
14. P. Filippakopoulos Selective inhibition of BET bromodomains Nature 23 2010 1067 1073
15. S. Muller Bromodomains as therapeutic targets Expert Rev. Mol. 13 2011 e29
16. L. Gratton Hot Spots. Why Some Teams, Workplaces and Organizations Buzz with Energy and Others Don't 2007 Berret Koehler Publishers Inc San Francisco